Citi opens ‘catalyst watch’ on Teva ahead of PDUFA date
Citi analyst Liav Abraham opened a “catalyst watch” on Teva Pharmaceutical ahead of the September 16 PDUFA date for fremanezumab for the prophylaxis of episodic and chronic migraine. The analyst has a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.